Navigation Links
NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Date:9/11/2007

SOPHIA ANTIPOLIS, France, Sept. 11 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today reported that TOPIGEN Pharmaceuticals Inc. has disclosed promising top-line results from its first phase 2 clinical study for TPI-1020, a new chemical entity licensed from NicOx which is a novel respiratory anti- inflammatory. These results showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects, which could be beneficial in TOPIGEN's target indication of Chronic Obstructive Pulmonary Disease (COPD). TOPIGEN plans to initiate a phase 2 study in patients with COPD during the second half of 2007 (see TOPIGEN's press release enclosed).

Damian Marron, Vice-President of Corporate Development at NicOx, declared: "These results indicate that TPI-1020 is safe and well tolerated in patients with respiratory disease and confirm its potential for enhanced clinical efficacy, as previously suggested by preclinical models of COPD. These positive data demonstrate the potential of NicOx' technology in the respiratory area and the quality of our alliance with TOPIGEN, whose expertise in this therapeutic area has been invaluable. NicOx and TOPIGEN are excited by this opportunity to develop an effective treatment for the millions of people suffering from COPD and looks forward to the initiation of a new trial in this indication later this year."

This trial was initiated in May 2006 and was a 21-day, multi-center, double blind trial in asthmatic smokers who were randomized to receive repeated and ascending doses of either inhaled TPI-1020 or budesonide, a conventional corticosteroid which is used in respiratory disorders (see press release of May 23, 2006). The top-line results of this trial revealed a good safety and tolerability profile, in addition to certain anti-inflammatory effects which could be beneficial in the treatment of COPD. TOPIGEN plans to initiate a phase 2 trial for TPI-1020 in COPD during the second half of 2007.

About C
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... British Columbia , May 26, 2015 /PRNewswire/ ... announced today that it has filed a provisional ... Trademark Office ("USPTO") relating to the treatment of ... natural cannabinoid compounds developed by InMed. ... Chief Scientific Officer, commented, "We are excited to ...
(Date:5/22/2015)... 22, 2015  Research and Benchmarking firm, Best ... Medical Affairs Roundtable on Thursday, May 28th ... roundtable to discuss "Medical Affairs, Role in Health ... Medical Affairs Consortium provides Medical Affairs leaders with ... challenges they face. The consortium has developed a ...
(Date:5/22/2015)... mayo de 2015 Dipexium Pharmaceuticals, ... farmacéutica de fase tardía centrada en el ... 0.8%), y colaboradores de investigación clínica, han ... el diseño innovador de los ensayos pivotales ... evalúan Locilex®, su nuevo péptido de antibiótico ...
Breaking Medicine Technology:InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 2InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 3Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6
(Date:5/26/2015)... 26, 2015 U.S. Food and Drug ... United States are extensive and can be difficult to ... helps medical device companies comply with FDA regulations, compiled ... companies navigate FDA requirements. , 1. Start researching ... States can be a lengthy process depending on the ...
(Date:5/26/2015)... Dearborn, MI (PRWEB) May 26, 2015 ... pleased to announce the launch of their new and ... practice to existing and potential patients. Dearborn Ear, Nose ... design’ that allows visitors to view the website seamlessly ... , Additional improvements to the Dearborn Ear, Nose ...
(Date:5/25/2015)... La. (PRWEB) May 26, 2015 Author Vincent ... number of people today are overweight, and many of them ... health. He also knows that most people don’t realize the ... environmental hazards and man-made toxins that exist. There ... don’t realize exactly how serious tobacco is.” , In “ ...
(Date:5/25/2015)... NY (PRWEB) May 26, 2015 ... Lisa Ferrara, Ph.D., as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... to welcome Lisa into this exceptional group of professional ...
(Date:5/25/2015)... 24Hr HomeCare is proud to announce ... & COO, and Ryan Iwamoto, Co-Founder & CMO, are ... Year® 2015 Awards in Greater Los Angeles. The award ... in innovation, financial performance, and a personal commitment to ... of the ongoing success of our organization,” said Co-Founder ...
Breaking Medicine News(10 mins):Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4Health News:Dearborn Ear, Nose & Throat Launches ‘Responsive Design’ Website 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2
... July 10 The American people continue to move to the pro-life ... Knights of Columbus and Marist Poll. , , The poll mirrored ... than as pro-choice, and that the vast majority of Americans favor restricting ... , 86% of Americans ...
... 10 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com ... A Vaccine of 2009 was delivered to India, by the ... India this year by the company. The first batch was ... are recommended to receive Hepatitis A vaccine, including people at ...
... kicking motion yields surprising clues as to why , FRIDAY, ... have different patterns of injuries, and now U.S. researchers think ... examine the kicking motion in male and female soccer players, ... finding that could help prevent injuries in the future. , ...
... America, Inc., a leading medical diagnostic instrument manufacturer ... of Jim Cusack as Director of Business Development ... of Marketing & Medical Affairs, Sysmex America. ... the company,s existing business partnerships and in identifying ...
... Surfers, cancer survivors and supporters will gather ... with a special purpose: to show their support for the fight ... they will place their surfboards in the sand, one-by-one, nose-to-tail, with ... The line will start at Scripps Pier and continue down La ...
... Boston University School of Medicine (BUSM) and collaborators have ... ,EUK-400 series, which could someday be used to prevent ... brains of radiological terrorism victims. The findings, which appear ... Biological Inorganic Chemistry , describe new agents which can ...
Cached Medicine News:Health News:New Poll Shows Americans Continuing to Move Toward Pro-Life Position on Abortion 2Health News:Hard To Treat Diseases (HTDS.PK) Completes India Order 2Health News:Hard To Treat Diseases (HTDS.PK) Completes India Order 3Health News:Soccer Injuries Differ by Gender 2Health News:Sysmex America Names Industry Veteran to Business Development Post 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 2Health News:Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug. 9 3Health News:New oral agents may prevent injury after radiation exposure 2
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Sandhill Scientific offers a comprehensive selection of solid state and water perfused catheters for both adult & pediatric applications.Contact Sandhill Scientific for full details...
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator....
Medicine Products: